Calendario›CORT›CORT125134

CORT125134

Study to Evaluate CORT125134 in Participants With Cushing's Syndrome

Ensayo de CORCEPT THERAPEUTICS INC en Sindrome de Cushing.

Más ensayos de: Síndrome de Cushing.

Fase

Fase 2

Estado

Completado

Participantes

35

previstos

Centros

25

Fin del objetivo primario

sep 2018

fecha real

Qué significa cada fase y cada estado.

Estudio de intervención, no aleatorizado, abierto. Comenzó en jun 2016.

Qué mide

Percentage of Participants With One or More Adverse Events (Group 1: up to Week 16; Group 2: up to Week 20) (del registro, en inglés)

Cómo lo describe el promotor

En el documentoEn inglés, del registroCushing's syndrome is a relatively rare disorder caused by prolonged exposure to high levels of the glucocorticoid hormone cortisol. Cushing's syndrome may result from elevated endogenous or exogenous sources of cortisol. Endogenous Cushing's syndrome resulting from cortisol overproduction by the adrenal glands is the subject of this protocol. Patients with exogenous Cushing's syndrome, which develops as a side effect of chronic administration of high doses of glucocorticoids, were not eligible for enrollment in this study. The purpose of this study was to evaluate the safety and efficacy of CORT125134 for treatment of endogenous Cushing's syndrome. The multicenter study was conducted in the United States and in Europe.

Más ensayos de CORT

Todos los de CORT, en su ficha.

Ficha completa en ClinicalTrials.gov (NCT02804750), actualizada en oct 2019.